Pipeline

LCB-Pharma is currently involved in the discovery and development of novel molecules aimed at a number of undisclosed pharmaceutical targets in the therapeutic areas of oncology and cardiovascular diseases.

 

LCB-Pharma owns a large family of novel nucleoside analogues protected by patents.   These series of molecular prototypes are part of the medicinal chemistry platform.  Quat, Pro-Quat, Quat-Net, Pro-Quat-Net.